Medivir AB Announces Data From Two Phase 3 Studies With Simeprevir in Hepatitis C Subpopulations – HCV/HIV Co-Infected and Genotype 4 Infected Patients

Published: Oct 18, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Stockholm, Sweden — Medivir AB (OMX: MVIR) today announced preliminary data from two phase III studies conducted by Janssen R&D Ireland evaluating simeprevir in genotype 4 chronic hepatitis C in adult patients with compensated liver disease, and in genotype 1 hepatitis C and HIV-1 co-infected adult patients. The data were presented today at the ongoing European AIDS Conference (EACS), October 16 -19 in Brussels.

Help employers find you! Check out all the jobs and post your resume.

Back to news